在一项体内药物相互作用研究中，作为CYP3A底物的沉淀抑制剂，需要多次给予400毫克酮康唑。 - Suppr

Suppr

超能文献

The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study.

作者信息

Oo Charles, Chen Ya-Chi

出版信息

J Clin Pharmacol. 2009 Mar;49(3):368-9; author reply 370. doi: 10.1177/0091270008325931.

DOI:10.1177/0091270008325931

PMID:19246734

Abstract

摘要

相似文献

The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study.在一项体内药物相互作用研究中，作为CYP3A底物的沉淀抑制剂，需要多次给予400毫克酮康唑。

J Clin Pharmacol. 2009 Mar;49(3):368-9; author reply 370. doi: 10.1177/0091270008325931.

Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.酮康唑对CYP3A底物药代动力学抑制的定量评估：一项模拟研究。

J Clin Pharmacol. 2009 Mar;49(3):351-9. doi: 10.1177/0091270008331196.

The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs.酮康唑在犬体内的药代动力学及其对咪达唑仑和芬太尼药代动力学的影响。

J Vet Pharmacol Ther. 2010 Feb;33(1):42-9. doi: 10.1111/j.1365-2885.2009.01105.x.

Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration.通过分开酮康唑和布地奈德的给药时间来降低酮康唑对布地奈德药代动力学的抑制作用。

Clin Pharmacol Ther. 2000 Jul;68(1):13-7. doi: 10.1067/mcp.2000.106895.

Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.酮康唑以咪达唑仑作为探针药物时，会导致CYP3A表型状态不佳。

Ther Drug Monit. 2006 Apr;28(2):255-61. doi: 10.1097/01.ftd.0000194497.55269.d9.

The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.当给予强效 CYP3A 自诱导剂和典型 CYP3A 抑制剂酮康唑时，对代谢清除率的影响。

Drug Metab Dispos. 2012 Oct;40(10):1945-52. doi: 10.1124/dmd.112.046060. Epub 2012 Jul 12.

Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.开发一种体内临床前筛选模型以评估外源性物质的吸收和首过肝提取率。II. 使用酮康唑鉴定猴体内P-糖蛋白/CYP3A限制的生物利用度。

Drug Metab Dispos. 2004 Feb;32(2):172-7. doi: 10.1124/dmd.32.2.172.

Multiple oral dosing of ketoconazole increases dog exposure to ivermectin.多次口服酮康唑会增加犬只对伊维菌素的暴露量。

J Pharm Pharm Sci. 2007;10(3):311-8.

Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm.酮康唑不同给药时长对咪达唑仑单剂量药代动力学的影响：缩短模式

J Clin Pharmacol. 2009 Apr;49(4):398-406. doi: 10.1177/0091270008331133. Epub 2009 Feb 26.

Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies.伊曲康唑和克拉霉素可替代酮康唑用于临床 CYP3A 抑制研究。

Clin Pharmacol Ther. 2014 May;95(5):473-6. doi: 10.1038/clpt.2014.41.

引用本文的文献

Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions.多西他赛、环磷酰胺和表柔比星：群体药代动力学模型在药物相互作用中的应用，以获得新的认识。

J Pharmacokinet Pharmacodyn. 2024 Aug;51(4):367-384. doi: 10.1007/s10928-024-09912-z. Epub 2024 Mar 30.

Prediction of Drug-Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation.使用基于生理的药代动力学建模与模拟预测替戈拉赞的药物相互作用潜力

Pharmaceutics. 2021 Sep 16;13(9):1489. doi: 10.3390/pharmaceutics13091489.

Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system.酮康唑对每周一次给予丁丙诺啡透皮贴剂后丁丙诺啡药代动力学特征的影响。

Clin Drug Investig. 2012 Sep 1;32(9):583-92. doi: 10.1007/BF03261913.

Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.口服奈拉替尼与酮康唑合用在健康受试者中的药代动力学。

Br J Clin Pharmacol. 2011 Apr;71(4):522-7. doi: 10.1111/j.1365-2125.2010.03845.x.

Quantitative clinical pharmacology is transforming drug regulation.定量临床药理学正在改变药物监管。

J Pharmacokinet Pharmacodyn. 2010 Dec;37(6):617-28. doi: 10.1007/s10928-010-9171-3. Epub 2010 Oct 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验